Basic Micronase Information

• INN (International Nonproprietary Name): Glyburide (also known as glibenclamide in several international markets).
• Brand Names Available In United States: Micronase (discontinued; generics available), Diabeta, Glynase Pres-Tab.
• ATC Code: A10BB09.
• Forms & Dosages: Tablets 1.25 mg, 2.5 mg, 5 mg; oral only.
• Manufacturers In United States: Originally Upjohn; now produced by generic manufacturers such as Teva, Mylan, Sandoz and others.
• Registration Status In United States: Micronase brand was approved historically but is discontinued; generic glyburide products remain FDA-approved.
• OTC / Rx Classification: Prescription only (Rx) in nearly all markets.

Key Findings From Recent Trials

Major 2022–2026 Studies

Patients and clinicians ask whether glyburide still has a role given newer therapies and shifting guidelines.

Recent randomized trials and large observational analyses through 2024 prioritized three outcome domains for glyburide: glycemic efficacy, hypoglycemia risk, and cardiovascular outcomes.

Meta-analyses and head-to-head comparisons in the early 2020s consistently compared sulfonylureas to incretin-based agents and SGLT2 inhibitors.

Main Outcomes

Glyburide commonly produced A1c reductions in the range of about 1.0–1.5% at typical dosing (2.5–20 mg/day).

Incremental A1c benefit diminished at higher doses, supporting conservative titration toward the 20 mg/day maximum when needed.

Comparative trend data in the 2020s favored incretin-based agents and SGLT2 inhibitors for cardiovascular and renal benefits and for a lower hypoglycemia burden.

Safety Observations

Across trials and observational data, the dominant safety signal for glyburide was severe and sometimes prolonged hypoglycemia, especially in elderly patients and those with renal impairment.

Weight gain was commonly reported in sulfonylurea-treated groups compared with some newer agents.

Regulatory and prescribing patterns reflect the U.S. brand discontinuation (Micronase) while generics remain available and used where cost or access are primary concerns.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask how Micronase lowers blood sugar and why it can cause low blood sugar episodes.

Glyburide works by telling the pancreas to release more insulin, making it helpful when the body still makes insulin but not enough.

That same stimulation explains why low blood sugar can happen if meals are skipped or kidney function slows drug clearance.

Scientific Breakdown

Glyburide is a second-generation sulfonylurea with ATC code A10BB09 that targets pancreatic β-cells.

The drug binds the sulfonylurea receptor type 1 (SUR1), which is part of the ATP-sensitive K+ channel complex on β-cell membranes.

β‑Cell Potassium Channel Effect

Binding to SUR1 causes ATP-sensitive KATP channels to close, which depolarizes the β-cell membrane.

Membrane depolarization opens voltage-gated calcium channels and increases intracellular calcium concentration.

Downstream Insulin Release

Rising intracellular Ca2+ triggers exocytosis of insulin-containing granules and increases circulating insulin levels.

Because glyburide depends on residual β-cell function, it is ineffective in type 1 diabetes and in diabetic ketoacidosis, which are absolute contraindications.

The pharmacology explains typical onset, dosing strategies (once daily or divided doses from 1.25–20 mg/day), and the drug’s propensity to cause hypoglycemia when caloric intake, renal function, or interacting medicines change.

Scope Of Approved & Off-Label Use

United States Approvals

Glyburide is approved for the treatment of type 2 diabetes mellitus as an oral hypoglycemic agent.

The Micronase brand was historically marketed in the United States in 1.25 mg, 2.5 mg, and 5 mg tablets but is now discontinued as a brand; generic glyburide remains prescription-only and available.

Indications are limited to adults with type 2 diabetes where diet, exercise, and other agents have not achieved control; it is contraindicated in type 1 diabetes and DKA.

Notable Off-Label Trends

Off-label use of glyburide is limited because the mechanism and contraindications are well defined.

In resource-constrained settings, glibenclamide remains in use where cost dictates therapy, and it is sometimes used for neonatal hypoglycemia protocols in select regions, though safety evidence varies.

International nomenclature differs—“glibenclamide” is common in EU and Canada while “glyburide” is used in U.S. labeling—important to check when procuring or comparing products online.

Dosage Strategy

General Dosing

Glyburide tablets are commonly available in 1.25 mg, 2.5 mg, and 5 mg strengths.

Initial adult dosing typically starts at 2.5–5 mg once daily, with maintenance ranges from 1.25 mg up to 20 mg per day, either once or divided into two doses.

The maximum recommended dose is 20 mg per day and titration should be gradual to limit hypoglycemia.

Condition-Specific Dosing

When adding glyburide to metformin, start low—often 2.5 mg—and titrate based on fasting glucose and hypoglycemia symptoms.

Elderly patients should begin at the lowest practical dose, for example 1.25 mg, with close glucose monitoring due to increased sensitivity to hypoglycemia.

Renal impairment is a major concern; glyburide is relatively contraindicated in significant renal dysfunction because metabolites can prolong hypoglycemia.

In hepatic impairment, start lower and titrate slowly with careful glucose checks.

Practical tips include taking glyburide with food to reduce GI upset and lower the risk of low blood sugar when meals are delayed.

If a dose is missed, take it when remembered unless it is near the next scheduled dose, and never double the next dose to compensate.

For overdose presenting as severe hypoglycemia, seek emergency care and treat promptly with oral glucose if the patient is conscious or IV dextrose if warranted.

Safety Protocols

Contraindications

Do not use glyburide in type 1 diabetes or diabetic ketoacidosis.

Known hypersensitivity to sulfonylureas is an absolute contraindication.

Significant renal or hepatic impairment, pregnancy, and breastfeeding are also absolute contraindications per product labeling and standard guidance.

Exercise caution in G6PD deficiency because of hemolysis risk, in adrenal or pituitary insufficiency, and in patients with malnutrition or irregular caloric intake.

Adverse Effects

Hypoglycemia is the most clinically significant adverse effect and can be severe and prolonged, particularly for older adults and those with reduced renal function.

Other common adverse effects include weight gain, nausea, vomiting, heartburn, mild skin rashes, headache, and dizziness.

Monitoring should include self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) during dose changes and periodic checks of renal and hepatic function where clinically indicated.

For high-risk patients, consider alternative agents with lower hypoglycemia risk and document shared decision-making about risks and benefits.

Interaction Mapping

Food Interactions

There are no pharmacologically critical food interactions requiring avoidance, but taking glyburide with food helps reduce the risk of hypoglycemia and gastrointestinal upset.

Skipping meals or fasting increases hypoglycemia risk because glyburide can stimulate insulin release regardless of immediate glucose intake.

Drug Combinations To Avoid

Combining glyburide with other hypoglycemic agents such as insulin or meglitinides should be done cautiously because of additive hypoglycemia risk.

Certain antibiotics like fluoroquinolones, azole antifungals, NSAIDs, and warfarin have been associated with increased hypoglycemia risk or altered glyburide metabolism and should prompt review.

Glyburide is hepatically metabolized, so strong CYP inhibitors or inducers can change exposure and clinical effect.

Alcohol can intensify hypoglycemia and may cause disulfiram-like reactions with sulfonylureas.

Before dispensing, review the full medication list for polypharmacy and counsel patients to report any new prescriptions or OTC medications.

Patient Experience Analysis

Survey Data

Patient surveys show that glyburide delivers measurable A1c reductions at a low out-of-pocket cost, which appeals to cost-sensitive patients.

However, satisfaction is often tempered by worry over hypoglycemia and by weight gain associated with sulfonylureas.

Elderly patients report higher rates of symptomatic hypoglycemia that sometimes lead to medication discontinuation.

Forum Trends

Online patient forums frequently discuss brand names such as Micronase, DiaBeta, and Glynase, and patients ask about switching between them or to newer classes like GLP-1 or SGLT2 agents.

Common patient tips include keeping glucose tablets on hand, having a bedtime snack to prevent nocturnal hypoglycemia, and asking providers about alternatives when hypoglycemia risk is high.

E-commerce searches often include terms like “Micronase 5 mg price” or “Micronase generic equivalent,” reflecting cost-driven behavior.

Distribution & Pricing Landscape

Micronase as a brand is discontinued in the United States, but generic glyburide remains widely produced by manufacturers such as Teva, Mylan, and Sandoz.

Tablets are commonly packaged in blister packs or bottles in strengths of 1.25 mg, 2.5 mg, and 5 mg.

Generic glyburide is inexpensive compared with newer antidiabetic medications, which contributes to continued use in cost-sensitive and resource-limited settings.

When buying online, verify FDA approval and the NDC number to confirm authenticity and correct strength.

Store glyburide at room temperature (20–25°C / 68–77°F) and protect from moisture during transport and storage.

Alternative Options

Comparison Table

• Metformin: First-line therapy; weight neutral or modest weight loss and low hypoglycemia risk.
• Glipizide/Gliclazide: Other sulfonylureas with similar A1c lowering; gliclazide may have lower hypoglycemia risk in some studies.
• Repaglinide: A meglitinide with shorter action and meal-timed dosing that reduces prolonged hypoglycemia risk.
• DPP-4, GLP-1, SGLT2 Inhibitors: Newer classes with minimal hypoglycemia and favorable cardiovascular/renal profiles but higher cost.

Pros And Cons

Glyburide advantages include low cost, oral dosing convenience, and predictable A1c reduction of approximately 1.0–1.5% for many patients.

Key disadvantages are higher hypoglycemia risk, weight gain, and contraindications for patients with significant renal or hepatic impairment and for pregnant or breastfeeding women.

Choose alternatives when hypoglycemia risk, cardiovascular or renal comorbidities, or patient preference and affordability favor newer agents.

Regulatory Status

In the United States, the Micronase brand was approved historically but has been discontinued; generic glyburide products remain FDA-approved and prescription-only.

Internationally, glyburide is labeled either as glyburide or glibenclamide depending on jurisdiction and carries ATC code A10BB09.

Regulatory labeling emphasizes contraindications including type 1 diabetes, DKA, pregnancy, breastfeeding, and recommends caution in renal and hepatic impairment.

Post-market surveillance continues to monitor severe hypoglycemia reports and interactions that can increase clinical risk.

Consolidated FAQ

Is Micronase Still Available?

The Micronase brand is discontinued in the U.S., but generic glyburide remains available.

What Strengths Exist?

Glyburide tablets commonly come in 1.25 mg, 2.5 mg, and 5 mg strengths.

Who Should Not Take It?

Patients with type 1 diabetes, DKA, significant renal or hepatic impairment, or those who are pregnant or breastfeeding should not take glyburide.

How To Manage A Missed Dose?

Take the missed dose when remembered unless it is close to the next scheduled dose; do not double the next dose.

What To Do For Hypoglycemia?

Treat mild hypoglycemia with 15–20 grams of fast-acting carbohydrate, recheck blood glucose in 15 minutes, and repeat if needed.

For severe hypoglycemia with unconsciousness, administer glucagon if available and seek emergency care for persistent episodes.

Clinical Pearls

Start at the lowest dose in elderly patients and monitor closely.

Avoid glyburide when renal function is significantly reduced and consider alternatives with a lower hypoglycemia risk if comorbidities warrant.

When comparing products online, search both “glyburide” and “glibenclamide” to ensure correct procurement and pricing.

Visual Guide

Recommended infographic elements include a mechanism flowchart: SUR1 → KATP channel → Ca2+ influx → insulin release.

A dosing ladder showing start doses of 1.25–5 mg with stepwise titration up to the 20 mg/day maximum is useful for patient handouts.

Contraindication icons should highlight pregnancy, renal failure, and type 1 diabetes.

A hypoglycemia action card should list symptoms, home treatments, and when to call 911.

Suggested charts include a bar chart comparing A1c reduction versus hypoglycemia rates for glyburide, glipizide, metformin, DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.

Storage & Transport

Store glyburide tablets at typical room temperature between 20–25°C (68–77°F) and protect from moisture.

Keep tablets in original blister packs or bottles to minimize humidity exposure and check expiration dates on arrival.

For international procurement, match the INN—glyburide versus glibenclamide—to avoid substitution errors.

Inactive ingredients may vary by manufacturer and include colloidal silicon dioxide, dibasic calcium phosphate, microcrystalline cellulose, sodium alginate, talc, and colorants for certain strengths.

Guidelines For Proper Use

Clinical Prescribing Checklist

Confirm the diagnosis of type 2 diabetes and that residual β-cell function is present.

Review renal and hepatic function before starting therapy and periodically thereafter.

Evaluate pregnancy and lactation status and check for hypersensitivity to sulfonylureas.

Review the full medication list for potential interactions that raise hypoglycemia risk.

Start at the lowest effective dose—consider 1.25 mg in older adults—and schedule baseline and follow-up SMBG or A1c testing.

Document shared decision-making regarding hypoglycemia risk versus cost and convenience.

Patient Counseling Points

Explain in plain language that glyburide stimulates insulin release and that this is why low blood sugar can occur.

Teach hypoglycemia recognition—sweating, tremor, rapid heartbeat, confusion—and action steps including fast-acting carbs and when to use glucagon.

Advise consistent meal patterns, carrying quick-acting carbohydrates, avoiding excess alcohol, and reporting any new medications.

Clarify dosing ranges (1.25–20 mg/day) and storage instructions (store at 20–25°C, protect from moisture).

Inform patients that Micronase brand may be discontinued but that generic glyburide is commonly used and therapeutically equivalent in many situations.

Quality Assurance

Reassess therapy at regular intervals and consider switching to metformin first-line or to a newer agent such as a GLP-1 or SGLT2 inhibitor when comorbidities or hypoglycemia risk make glyburide less suitable.

Access And Ordering

Many patients ask where they can buy glyburide at a reasonable price and how quickly it will arrive.

Generic glyburide is widely available through retail, mail-order, and e-commerce pharmacies, normally as prescription-only products in the U.S.

For online purchases, always confirm FDA approval and check NDC codes and manufacturer details to verify authenticity.

In the pharmacy's online store, micronase (generic glyburide) can be ordered with discreet delivery to the United States in 5-14 days, and pharmacy staff can advise on prescription requirements and alternatives.

Delivery Across United States